CXCR4抑制剂AMD3465调节肺癌细胞株增殖、侵袭的实验研究

doi:10.3877/cma.j.issn.1674-6902.2017.04.004

目的

探讨CXCR4抑制剂AMD3465对肺癌细胞株增殖、侵袭的影响。

方法

培养肺癌细胞株A549并分为AMD3465组、对照组；分别用含有三种不同剂量(50 、100、200 mg/L)AMD3465的DMEM处理以及用不含药物的DMEM处理。处理后12、24、48 h，检测细胞的增殖活力和侵袭数目；处理后48 h，检测细胞中增殖及侵袭基因的mRNA表达量。

结果

处理后12、24、48 h，三种不同剂量(50、100、200 mg/L)AMD3465组细胞的OD值均显著低于对照组、侵袭数目均显著少于对照组，AMD3456剂量较低时OD值、侵袭数目与对照组差距均大于AMD3456剂量较高时(P<0.05)；处理后48 h，50 mg/L AMD3465组、100 mg/L AMD3465组、200 mg/L AMD3465组细胞中CyclinD1、PCNA、Ki-67、CatB、MMP2、MMP9、MMP13的mRNA表达量均显著低于对照组；AMD3456剂量较低时细胞中CyclinD1、PCNA、Ki-67、CatB、MMP2、MMP9、MMP13的mRNA表达量与对照组差距均大于AMD3456剂量较高时(P<0.05)。

结论

CXCR4抑制剂AMD3465能够有效抑制肺癌细胞株的增殖、侵袭。

关键词: 支气管肺癌, CXC受体4, 增殖, 侵袭

Objective

To study the effect of CXCR4 inhibitor AMD3465 on proliferation and invasion of lung carcinoma cell lines.

Methods

The lung carcinoma cell line A549 was cultured and divided into 50 mg/L AMD3465 group, 100 mg/L AMD3465 group, 200 mg/L AMD3465 group treated with DMEM containing different dosage of AMD3465 and control group treated DMEM without drug. After 12 h, 24 h and 48 h, the proliferation and invasion number of the cells were detected. After 12 h, the mRNA expression of cell proliferation and invasion genes were detected.

Results

12 h, 24 h, 48 h after treatment, OD values of 50 mg/L AMD3465 group, 100 mg/L AMD3465 group, 200 mg/L AMD3465 group were significantly lower than the control group, invasion number were significantly less than the control group, the differences of OD values and invasion number between control group and lower dosage ADM3456 group were larger than higher dosage AMD3465(P<0.05); 48 hours after treatment, mRNA expression of CyclinD1, PCNA, Ki-67 cells, CatB, MMP2, MMP9, MMP13 of 50mg/L AMD3465 group, 100 mg/L AMD3465 group, 200 mg/L AMD3465 group were significantly lower than the control group; the differences of mRNA expression of CyclinD1, PCNA, Ki-67 cells, CatB, MMP2, MMP9, MMP13 between control group and lower dosage ADM3456 group were larger than higher dosage AMD3465(P<0.05).

Conclusion

CXCR4 inhibitor AMD3465 can effectively inhibit the proliferation and invasion of lung carcinoma cell lines.

Key words: Bronchogenic carcinoma, CXC receptor 4, Proliferation, Invasion

表1 两组细胞的增殖活力比较

剂量及组别		例数	12 h	24 h	48 h
50 mg/L AMD3465组		5	0.312±0.055^a	0.289±0.036^a	0.336±0.049^a
100 mg/L AMD3465组		5	0.398±0.064^ab	0.447±0.081^ab	0.483±0.068^ab
200 mg/L AMD3465组		5	0.452±0.077^abc	0.502±0.089^abc	0.593±0.077^abc
?	对照组	5	0.523±0.078	0.641±0.089	0.702±0.093

表1 两组细胞的增殖活力比较

剂量及组别		例数	12 h	24 h	48 h
50 mg/L AMD3465组		5	0.312±0.055^a	0.289±0.036^a	0.336±0.049^a
100 mg/L AMD3465组		5	0.398±0.064^ab	0.447±0.081^ab	0.483±0.068^ab
200 mg/L AMD3465组		5	0.452±0.077^abc	0.502±0.089^abc	0.593±0.077^abc
?	对照组	5	0.523±0.078	0.641±0.089	0.702±0.093

表2 两组细胞的侵袭能力比较

剂量及组别		例数	12 h	24 h	48 h
50 mg/L AMD3465组		5	78.49±9.32^a	80.24±9.31^a	83.19±9.72^a
100 mg/L AMD3465组		5	103.22±16.58^ab	114.58±12.39^ab	123.15±14.58^ab
200 mg/L AMD3465组		5	128.65±16.84^abc	145.24±19.74^abc	189.32±22.36^abc
?	对照组	5	156.22±22.31	195.62±25.27	247.58±31.28

表2 两组细胞的侵袭能力比较

剂量及组别		例数	12 h	24 h	48 h
50 mg/L AMD3465组		5	78.49±9.32^a	80.24±9.31^a	83.19±9.72^a
100 mg/L AMD3465组		5	103.22±16.58^ab	114.58±12.39^ab	123.15±14.58^ab
200 mg/L AMD3465组		5	128.65±16.84^abc	145.24±19.74^abc	189.32±22.36^abc
?	对照组	5	156.22±22.31	195.62±25.27	247.58±31.28

表3 两组细胞中增殖基因的表达量比较

剂量及组别		例数	CyclinD1	PCNA	Ki-67
50 mg/L AMD3465组		5	0.35±0.07^a	0.42±0.08^a	0.29±0.04^a
100 mg/L AMD3465组		5	0.57±0.08^ab	0.64±0.09^ab	0.52±0.07^ab
200 mg/L AMD3465组		5	0.82±0.09^abc	0.78±0.06^abc	0.85±0.11^abc
?	对照组	5	1.07±0.14	0.95±0.11	1.10±0.18

表3 两组细胞中增殖基因的表达量比较

剂量及组别		例数	CyclinD1	PCNA	Ki-67
50 mg/L AMD3465组		5	0.35±0.07^a	0.42±0.08^a	0.29±0.04^a
100 mg/L AMD3465组		5	0.57±0.08^ab	0.64±0.09^ab	0.52±0.07^ab
200 mg/L AMD3465组		5	0.82±0.09^abc	0.78±0.06^abc	0.85±0.11^abc
?	对照组	5	1.07±0.14	0.95±0.11	1.10±0.18

表4 两组细胞中侵袭基因的表达量比较

剂量及组别	例数	CatB	MMP2	MMP9	MMP13
50 mg/L AMD3465组	5	0.42±0.08^a	0.33±0.06^a	0.56±0.09^a	0.38±0.07^a
100 mg/L AMD3465组	5	0.64±0.08^ab	0.50±0.07^ab	0.72±0.09^ab	0.51±0.08^ab
200 mg/L AMD3465组	5	0.80±0.11^abc	0.77±0.09^abc	0.85±0.12^abc	0.78±0.04^abc
对照组	5	1.15±0.18	1.05±0.17	1.08±0.14	0.98±0.11

表4 两组细胞中侵袭基因的表达量比较

剂量及组别	例数	CatB	MMP2	MMP9	MMP13
50 mg/L AMD3465组	5	0.42±0.08^a	0.33±0.06^a	0.56±0.09^a	0.38±0.07^a
100 mg/L AMD3465组	5	0.64±0.08^ab	0.50±0.07^ab	0.72±0.09^ab	0.51±0.08^ab
200 mg/L AMD3465组	5	0.80±0.11^abc	0.77±0.09^abc	0.85±0.12^abc	0.78±0.04^abc
对照组	5	1.15±0.18	1.05±0.17	1.08±0.14	0.98±0.11

1	钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
2	Christensen NL, Jekunen A, Heinonen S, et al. Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison[J]. Acta Oncol, 2017, 56(7): 943-948.
3	Hackner K, Errhalt P, Mueller MR, et al. Canine scent detection for the diagnosis of lung cancer in a screening-like situation[J]. J Breath Res, 2016, 10(4): 046003.
4	Spaks A. Role of CXC group chemokines in lung cancer development and progression[J]. J Thorac Dis, 2017, 9(Suppl 3): 164-171.
5	Sterlacci W, Saker S, Huber B, et al. Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung[J]. Virchows Arch, 2016, 468(4): 463-471.
6	Rodriguez-Lara V, Ignacio GS, Cerbón Cervantes MA. Estrogen induces CXCR4 overexpression and CXCR4/CXL12 pathway activation in lung adenocarcinoma cells in vitro[J]. Endocr Res, 2017, 20: 1-13.
7	叶明宝，田俊强，常宏，等. SDF-1/CXCR4在膀胱癌组织中的表达及其与负性共刺激分子PD-L1、细胞凋亡和侵袭性的相关性研究[J]. 海南医学院学报，2017, 23 (6): 736-738，742.
8	Bamdad S, Khademi B, Chenari N, et al. Stromal cell derived factor-1, CXCR4 and CXCR7 gene transcripts in pterygia[J]. J Curr Ophthalmol, 2016, 29(1): 28-32.
9	Gu Q, He Y, Ji J, et al. Hypoxia-inducible factor 1α (HIF-1α) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1α/CXCR4 pathway in non-small cell lung carcinoma cells[J]. Oncotarget, 2015, 6(13): 10893-1907.
10	Li C, He B, Huang C, et al. Sex-Determining region Y-box 2 promotes growth of lung squamous cell carcinoma and directly targets cyclin D1[J]. DNA Cell Biol, 2017, 36(4): 264-272.
11	Kim Y, Jin D, Lee BB, et al. Overexpression of β-catenin and cyclin D1 is associated with poor overall survival in patients with stage ⅠA-ⅡA squamous cell lung cancer irrespective of adjuvant chemotherapy[J]. J Thorac Oncol, 2016, 11(12): 2193-2201.
12	任洁，程春来，芦兰，等. 肺癌血清标志物PCNA及Bax的表达及与预后的关系[J]. 重庆医学，2017, 46(10): 1399-1401.
13	姜峰，杜然. TAP联合Ki-67对判断非小细胞肺癌患者预后的临床意义[J]. 临床与实验病理学杂志，2017, 33(1): 104-106.
14	Albert J, Bosque R, Crespo M, et al. Neutral and ionic platinum compounds containing a cyclometallated chiral primary amine: synthesis, antitumor activity, DNA interaction and topoisomerase I-cathepsin B inhibition[J]. Dalton Trans, 2015, 44(30): 13602-13614.
15	Pietruszewska W, Bojanowska-Poźniak K, Kobos J. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study[J]. Otolaryngol Pol, 2016, 70(3): 32-43.
16	Kerenidi T, Kazakou AP, Lada M, et al. Clinical significance of circulating osteopontin levels in patients with lung cancer and correlation with VEGF and MMP-9[J]. Cancer Invest, 2016, 34(8): 385-392.

[1]	江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[2]	郑嘉裕, 吴建杰, 李小娟, 曾恒达, 李国邦, 黄炯煅, 温星桥. hsa_circ_0090923在前列腺癌中的表达及其对前列腺癌细胞增殖和迁移的调控[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 276-283.
[3]	刘雪峰, 韩海峰, 杨硕, 逯景辉. 腹腔镜腹壁侵袭性纤维瘤病切除联合腹壁重建：单中心经验总结[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(04): 374-379.
[4]	梁开地, 缑文斌, 莫居容. 肺癌组织中细胞角蛋白18的表达及与预后的相关性[J]. 中华肺部疾病杂志(电子版), 2023, 16(05): 688-690.
[5]	孟原竹, 蒋国路, 陈小兵, 蒋莉. 肺结核合并侵袭性肺曲霉感染临床特征及危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 541-543.
[6]	蒙姣姣, 胡刚, 欧阳涣堃. 肺癌术前淋巴结转移及MWA手术效果预测分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 547-549.
[7]	卞天丹, 宋爽, 陶臻. 高毒力肺炎克雷伯菌分子学机制研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 438-441.
[8]	王玉琳, 孙晓容. 晚期肺癌大咯血输注垂体后叶素渗漏救治成功一例[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 451-452.
[9]	黄芳芳, 陈雅玫, 邓牡红, 石新华, 尚少梅. 肺癌患者上肢PICC相关性静脉血栓危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 324-328.
[10]	徐欣轶, 薛蓓, 蒋莉, 陈慧. NRI联合CFS评分对肺癌术后机械通气的预测分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 358-360.
[11]	余慧, 王静, 杜丹, 杨帆. 下调miR-301a-3p抑制人卵巢颗粒KGN细胞增殖和诱导凋亡的机制研究[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 137-143.
[12]	刘燕, 叶亚萍, 郑艳莉. 干扰LINC00466通过miR-493-3p/MIF抑制子宫内膜癌RL95-2细胞恶性生物学行为[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 151-158.
[13]	莫钊鸿, 翟航, 苏日顺, 孟泓宇, 罗豪, 陈文豪, 许瑞云. U2AF2表达对肝细胞癌增殖和迁移的影响及其与预后的关系[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 336-341.
[14]	邓世栋, 刘凌志, 郭大勇, 王超, 黄忠欣, 张晖辉. 沉默SNHG1基因对膀胱癌细胞增殖、凋亡、迁移和铁死亡的影响[J]. 中华临床医师杂志(电子版), 2023, 17(07): 804-811.
[15]	方辉, 李菲, 张帆, 魏强, 陈强谱. 外源性瘦素对梗阻性黄疸大鼠肠黏膜增殖的影响[J]. 中华临床医师杂志(电子版), 2023, 17(05): 575-580.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Experimental study of CXCR4 inhibitor AMD3465 regulating proliferation and invasion of lung carcinoma cell line

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Experimental study of CXCR4 inhibitor AMD3465 regulating proliferation and invasion of lung carcinoma cell line